0001192482-19-000424.txt : 20191113 0001192482-19-000424.hdr.sgml : 20191113 20191113205222 ACCESSION NUMBER: 0001192482-19-000424 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20191108 FILED AS OF DATE: 20191113 DATE AS OF CHANGE: 20191113 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Azarbarzin Kurt CENTRAL INDEX KEY: 0001792303 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39130 FILM NUMBER: 191215980 MAIL ADDRESS: STREET 1: C/O TELA BIO, INC. STREET 2: 1 GREAT VALLEY PARKWAY, SUITE 24 CITY: MALVERN STATE: PA ZIP: 19355 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: TELA Bio, Inc. CENTRAL INDEX KEY: 0001561921 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 455320061 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 1 GREAT VALLEY PARKWAY, SUITE 24 CITY: MALVERN STATE: PA ZIP: 19355 BUSINESS PHONE: 484-320-2930 MAIL ADDRESS: STREET 1: 1 GREAT VALLEY PARKWAY, SUITE 24 CITY: MALVERN STATE: PA ZIP: 19355 4 1 edgar.xml PRIMARY DOCUMENT X0306 4 2019-11-08 0001561921 TELA Bio, Inc. TELA 0001792303 Azarbarzin Kurt C/O HIGHCAPE PARTNERS QP, L.P. 10751 FALLS ROAD, SUITE 300 BALTIMORE MD 21093 1 0 0 0 Common Stock 2019-11-08 4 P 0 10220 13.00 A 12675 I By HighCape Partners, L.P. Common Stock 2019-11-08 4 P 0 75901 13.00 A 260808 I By HighCape Partners QP, L.P. Common Stock 2019-11-13 4 C 0 269 A 12944 I By HighCape Partners, L.P. Common Stock 2019-11-13 4 C 0 2931 A 15875 I By HighCape Partners, L.P. Common Stock 2019-11-13 4 C 0 19982 A 280790 I By HighCape Partners QP, L.P. Common Stock 2019-11-13 4 C 0 217816 A 498606 I By HighCape Partners QP, L.P. Series A Preferred Stock 2019-11-13 4 C 0 493357 0 D Common Stock 19982 0 I By HighCape Partners QP, L.P. Series A Preferred Stock 2019-11-13 4 C 0 6643 0 D Common Stock 269 0 I By HighCape Partners, L.P. Series B Preferred Stock 2019-11-13 4 C 0 5377928 0 D Common Stock 217816 0 I By HighCape Partners QP, L.P. Series B Preferred Stock 2019-11-13 4 C 0 72417 0 D Common Stock 2931 0 I By HighCape Partners, L.P. Warrant (right to buy) 1.16 2019-11-13 4 C 0 123653 0 D 2017-01-18 2027-01-18 Series B Preferred Stock 123653 0 I By HighCape Partners QP, L.P. Warrant (right to buy) 28.65 2019-11-13 4 C 0 123653 0 A 2017-11-13 2027-01-18 Common Stock 5008 123653 I By HighCape Partners QP, L.P. Warrant (right to buy) 1.16 2019-11-13 4 C 0 1665 0 D 2017-01-18 2027-01-18 Series B Preferred Stock 1665 0 I By HighCape Partners, L.P. Warrant (right to buy) 28.65 2019-11-13 4 C 0 1665 0 A 2019-11-13 2027-01-18 Common Stock 67 1665 I By HighCape Partners, L.P. Reflects 2,455 shares of common stock received by the reporting person as a payment-in-kind dividend on Series A Preferred Stock and Series B Preferred Stock exempt from reporting under Rule 16a-9(a). Reflects 183,907 shares of common stock received by the reporting person as a payment-in-kind dividend on Series A Preferred Stock and Series B Preferred Stock exempt from reporting under Rule 16a-9(a). Shares of Series A Preferred Stock automatically converted into shares of Common Stock at a 1-for-1 conversion rate upon the closing of the Issuer's initial public offering and had no expiration date. Shares of Series B Preferred Stock automatically converted into shares of Common Stock at a 1-for-1 conversion rate upon the closing of the Issuer's initial public offering and had no expiration date. Reflects 1-for-24.69 reverse stock split which became effective on October 28, 2019. Warrants exercisable for shares of Series B Preferred Stock automatically converted into warrants exercisable for shares of Common Stock upon the closing of the Issuer's initial public offering. /s/ Nora Brennan as attorney-in-fact for Matt Zuga 2019-11-13